Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Malte Peters, Chief Executive Officer and President of Tango Therapeutics

“It is encouraging to see that the clinical activity and tolerability observed in our initial June 2026 dataset has been confirmed with longer follow-up and in a larger patient population, affirming our belief that the response rate and durability observed with vopimetostat plus daraxonrasib surpass any published PDAC datasets, even in front-line settings”

Malte Peters, Chief Executive Officer and President of Tango Therapeutics

“Following discussions with the U.S. FDA, we are focused on initiating a planned registrational Phase 3 trial of vopimetostat with daraxonrasib in front-line patients with MTAP-deleted pancreatic cancer in the first half of 2027.”

Malte Peters, Chief Executive Officer and President of Tango Therapeutics

“Given the data generated to date, we view PRMT5 inhibition as an emerging backbone in combination treatment strategies in PDAC and beyond.”

Malte Peters, Chief Executive Officer and President of Tango Therapeutics

“As a leader in the development of PRMT5-targeted therapies, we are also encouraged by the potential combinations of vopimetostat with RAS inhibitors in MTAP wild-type tumors, which we believe could further expand the impact of PRMT5 inhibition across a broader population of patients with PDAC.”

Alexander Spira, Co-Director of the Virginia Cancer Specialists Research Institute, NEXT Oncology, an Avacare business, and principal investigator of the study

“For patients with pancreatic cancer, a highly aggressive malignancy that often progresses despite prior treatment, achieving durable disease control remains a significant challenge,”

Alexander Spira, Co-Director of the Virginia Cancer Specialists Research Institute, NEXT Oncology, an Avacare business, and principal investigator of the study

“In this updated analysis, the large majority of patients remained progression-free at nine months despite being heavily pretreated, with more than half receiving the combination as third-line therapy.”

Alexander Spira, Co-Director of the Virginia Cancer Specialists Research Institute, NEXT Oncology, an Avacare business, and principal investigator of the study

“Achieving this level of durability with an oral, chemotherapy-free regimen is particularly meaningful for patients and highlights the potential of a vopimetostat combination to redefine the standard of care in a disease that has been notoriously difficult to treat.”

Anna Berkenblit, Chief Scientific & Medical Officer of the Pancreatic Cancer Action Network (PanCAN)

“The depth and durability of responses reported with the vopimetostat and daraxonrasib combination are encouraging, particularly for patients who had already received multiple lines of treatment.”

Anna Berkenblit, Chief Scientific & Medical Officer of the Pancreatic Cancer Action Network (PanCAN)

“We are excited by the potential of this biomarker-driven, targeted therapy approach and believe these results warrant rapid evaluation in a larger, randomized Phase 3 trial.”

Anna Berkenblit, Chief Scientific & Medical Officer of the Pancreatic Cancer Action Network (PanCAN)

“The approval of daraxonrasib marked the beginning of a new era for the pancreatic cancer community after a long wait, and we are looking forward to the next major advance that will translate into meaningful progress for patients quickly.”